Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1930 • ACR Convergence 2021
Single-Cell Genomics Reveals a Shared Monocyte Interferon Program in a Subset of Patients with Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Lung Disease
Emely Verweyen¹, Kairavee Thakkar², Kashish Chetal², Sanjeev Dhakal³, Alexei Grom², Nathan Salomonis² and Grant Schulert², ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children hospital, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a clinically heterogenous disease and can be complicated by macrophage activation syndrome (MAS) and lung disease (LD) thought…
Abstract Number: 0249 • ACR Convergence 2021
Open-label, Long-term (10-year) Study of the Safety of Etanercept in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis
Jelena Vojinović¹, Joke Dehoorne², Violeta Panaviene³, Gordana Susic⁴, Gerd Horneff⁵, Valda Stanevicha⁶, Katarzyna Kobusinska⁷, Zbigniew Zuber⁸, Bogna Dobrzyniecka⁹, Jonathan Akikusa¹⁰, Tadej Avcin¹¹, Alberto Martini¹², Cecilia Borlenghi¹³, Edmund Arthur¹⁴, Svitlana Tatulych¹⁵, Chuanbo Zang¹⁶, Bonnie Vlahos¹⁶ and Nicolino Ruperto¹⁷, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Nis, Serbia, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Gent, Belgium, ³Paediatric Rheumatology International Trials Organisation (PRINTO), Vilnius, Lithuania, ⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Belgrade, Serbia, ⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁶Paediatric Rheumatology International Trials Organisation (PRINTO), Riga, Latvia, ⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Bydgoszcz, Poland, ⁸Paediatric Rheumatology International Trials Organisation (PRINTO), Lodz, Poland, ⁹Paediatric Rheumatology International Trials Organisation (PRINTO), Warsaw, Poland, ¹⁰Paediatric Rheumatology International Trials Organisation (PRINTO), Melbourne, Australia, ¹¹Paediatric Rheumatology International Trials Organisation (PRINTO), Ljubljana, Slovenia, ¹²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹³Pfizer, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁴Pfizer, Peapack, NJ, ¹⁵Pfizer, Groton, CT, ¹⁶Pfizer, Collegeville, PA, ¹⁷IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: CLIPPER2 was an 8-year, open-label extension of the phase 3b, multicenter, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in the…
Abstract Number: 0960 • ACR Convergence 2021
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, Mary Ellen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Marc Natter¹¹ and The STOP-JIA CARRA Registry Investigators¹², ¹Hackensack University Medical Center, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸Childhood Arthritis & Rheumatology Research Alliance (CARRA), New Orleans, LA, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Boston Children's Hospital, Boston, MA, ¹²Childhood Arthritis & Rheumatology Research Alliance (CARRA), Milwaukee, WS
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: 0251 • ACR Convergence 2021
A Comparative Study of the Validity of the DAS28-ESR and JADAS-27 Disease Activity Assessment Indexes for Juvenile Idiopathic Arthritis in Transition and Adults
Takako Miyamae¹, Eiichi Tanaka¹, Eisuke Inoue², Katsunori Ikari¹ and Masayoshi Harigai³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University School of Medicine, Tokyo, Japan
Background/Purpose: The 2020 Rheumatoid Arthritis Clinical Practice Guidelines by the Ministry of Health, Labour, and Welfare Research Group recommends the JADAS27 as a measure of…
Abstract Number: 0976 • ACR Convergence 2021
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: The impact of social determinants of health in juvenile idiopathic arthritis (JIA) remains poorly understood. Racial disparities exist in JIA, including increased pain and…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: 0253 • ACR Convergence 2021
Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
Nayimisha Balmuri¹, William Soulsby², Victoria Cooley³, Linda Gerber⁴, Erica Lawson² and Karen Onel¹, ¹Hospital for Special Surgery, New York, NY, ²University of California San Francisco, San Francisco, CA, ³Weil Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Children with rheumatoid factor (RF) positive polyarticular JIA (pJIA) are less likely to go into remission and more likely to develop erosive disease than…
Abstract Number: 0977 • ACR Convergence 2021
Enhancement of Patient and Clinician Partnerships in Juvenile Idiopathic Arthritis Management Using a Point-of-Care Dashboard: Development and Pilot Testing
Erica Lawson¹, Lisa Johnson², Jabeen Ahmad², Vincent Del Gaizo³, Brittany Donaldson⁴, Julie Eller⁵, Yukiko Kimura⁶, Cathy Knucken⁷, Tzielan Lee⁸, Corinne Pinter⁹, Doreen Tabussi¹⁰, Alysha Taxter¹¹ and Aricca Van Citters², ¹University of California San Francisco, San Francisco, CA, ²Dartmouth College, Lebanon, NH, ³Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁴Wake Forest University School of Medicine Brenner Children's, Winston Salem, NC, ⁵Arthritis Foundation, Washington, DC, ⁶Hackensack University Medical Center, New York, NY, ⁷Patient Partner, Byram, NJ, ⁸Stanford University School of Medicine, Palo Alto, CA, ⁹Patient Partner, Sugar Land, TX, ¹⁰Hackensack University Medical Center, Upper Saddle River, NJ, ¹¹Wake Forest Baptist Medical Center, Winston-Salem, NC
Background/Purpose: Health outcomes improve when people living with chronic conditions partner with their clinicians to coproduce care based on their values, preferences, goals, and the…
Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Elaine Flanagan¹, Rosemary Peterson², Susan Shenoi³, Helena Chang⁴, Kelly Wang⁴, Rebecca Trachtman⁴ and Karen Onel⁵, ¹Emory/CHOA, Atlanta, GA, ²Dell Children's Medical Center, Austin, TX, ³Seattle Children's Hospital, Seattle, WA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
Abstract Number: 1008 • ACR Convergence 2021
Synovial Fluid IL-36γ in Patients with Enthesitis Related Arthritis (ERA) Correlates with Disease Activity and Leads to Production of IL-6 by Fibroblast Like Synoviocytes
Amita Aggarwal, Sanjukta Majumder and Shivika Guleria, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: IL-36 has been implicated in the pathogenesis of spondyloarthropathies (SpA) like psoriasis and IBD. Enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA)…
Abstract Number: 0255 • ACR Convergence 2021
Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³CARRA, Durham, NC
Background/Purpose: Recent treat to target recommendations for the treatment of juvenile idiopathic arthritis (JIA) recommend frequent evaluation and treatment intensification until the disease activity target…
Abstract Number: 1009 • ACR Convergence 2021
Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis
Amelie Jule¹, Maria Taylor², Kacie Hoyt³, Kevin Wei⁴, Maria Gutierrez-Arcelus¹, Siobhan Case¹, Mia Chandler¹, Margaret Chang², Ezra Cohen¹, Fatma Dedeoglu¹, Olha Halyabar¹, Jonathan Hausmann⁵, Melissa Hazen¹, Erin Janssen¹, Jeffrey Lo², Mindy Lo¹, Esra Meidan², Jordan Roberts¹, Mary Beth Son¹, Robert Sundel², Pui Lee⁶, Talal Chatila¹, Peter Nigrovic¹, Deepak Rao⁴ and Lauren Henderson⁷, ¹Boston Children's Hospital, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Virginia Tech Carilion School of Medicine, Roanoke, VA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Boston Children's Hospital, Newton, MA, ⁷Division of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement (< 5 joints) in the first 6 months of disease. A subgroup…
Abstract Number: 0256 • ACR Convergence 2021
Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
Tala El Tal¹, Meghan Ryan², Brian Feldman³, Catherine Bingham⁴, Jon Burnham⁵, Michelle Batthish⁶, Danielle Bullock⁷, Kerry Ferraro⁸, Mileka Gilbert⁹, Beth Gottlieb¹⁰, Julia Harris¹¹, Melissa Hazen¹², Ronald Laxer¹³, Tzielan Lee¹⁴, Daniel Lovell¹⁵, Melissa Mannion¹⁶, Laura Noonan¹⁷, Edward Oberle¹⁸, Anne Paul¹⁹, Janalee Taylor²⁰, Jennifer Weiss²¹, Cagri Yildirim-Toruner²² and Esi Morgan²³, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²University of Minnesota, Vadnais Heights, MN, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Children's Hospital, Allentown, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Minnesota, Minneapolis, MN, ⁸Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Children's Mercy Kansas City, Overland Park, KS, ¹²Boston Children's Hospital, Boston, MA, ¹³SickKids, Toronto, ON, Canada, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ¹⁶University of Alabama at Birmingham, Birmingham, AL, ¹⁷Levine Children's Hospital/Carolinas Healthcare System, Charlotte, NC, ¹⁸Nationwide Children's Hospital, Columbus, OH, ¹⁹Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, ²⁰Cincinnati Children's Hospital, Cincinnati, OH, ²¹Hackensack University Medical Center, Hackensack, NJ, ²²Texas Children's Hospital/Baylor College of Medicine, Houston, TX, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and…
Abstract Number: 1012 • ACR Convergence 2021
Altered T Cell Responses, and Synergistic Regulation of Synovial Fibroblasts Function in Children with Down’s Syndrome-Associated Arthritis
Serena Foo¹, Achilleas Floudas², Aisling O' Brien¹, Sharon Ansboro¹, Ronan Mullan³, Douglas Veale⁴, Emma MacDermott⁵, Derek Deely⁶, Charlene Foley⁶, Orla Killeen⁶ and Ursula Fearon¹, ¹Trinity College Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ³Tallaght University Hospital, Dublin, Ireland, ⁴University College Dublin, Dublin, Ireland, ⁵Children’s Health Ireland (CHI) at Crumlin, Dublin, Ireland, ⁶Children's Health Ireland, Crumlin, Dublin, Ireland
Background/Purpose: Juvenile idiopathic arthritis (JIA) was thought to be the most common inflammatory arthritis in children. However an aggressive, erosive arthritis of little-known immunologic mechanism…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].